Krishnan Nandabalan, Director, 10% Owner at BioXcel Therapeutics, Inc. (BTAI), sold 119,200 shares at $22.32 ($2.6M) on 2023-01-05, disclosed to the SEC on 2023-01-06.
Open-market sale of $2.6M BTAI by Director, 10% Owner. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $21.59 | 24,290 | $524K | 20.0% |
| 2 | $21.59 | 24,290 | $524K | 20.0% |
| 3 | $22.21 | 9,821 | $218K | 8.3% |
| 4 | $22.21 | 9,821 | $218K | 8.3% |
| 5 | $22.32 | 25,089 | $560K | 21.3% |
| 6 | $22.32 | 25,089 |
| $560K |
| 21.3% |
| 7 | $22.93 | 800 | $18K | 0.7% |
| Total | $22.01 avg | 119,200 | $2.6M | 100% |
| Filing → |
| BTAI | SELL | 2021-06-29 | $29.2M | — | Filing → |
| BTAI | BUY | 2018-11-30 | $5K | — | Filing → |